This project aims to bring cutting-edge molecular diagnostics to Saudi Arabia using a 23-gene panel to detect key genetic ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

King Faisal Specialist Hospital & Research Centre (KFSHRC) in Saudi Arabia has entered a five-year partnership with the ...

A bladder ultrasound gives providers clues about how the bladder expands and holds urine. This article lists conditions ...

Bladder cancer is the ninth most common cancer worldwide, and the number of diagnosed incident cases is set to increase.

Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.

Lower abdominal visceral fat area (VFA), older age, and prolonged surgery are independent risk factors for developing ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a ...

The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years ...

Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months. On Nov. 6, 2024, ...

A recent study reveals that extended lymphadenectomy offers no survival advantage over standard lymphadenectomy for patients ...